BPC-157 vs LL-37
Research Verdict
LL-37 is the stronger research reference for the stated comparison criteria. BPC-157: 70+ rodent studies, single research group, no human efficacy data.
Quick Answers
Which is better, BPC-157 or LL-37?
LL-37 is the stronger research reference for the stated comparison criteria. BPC-157: 70+ rodent studies, single research group, no human efficacy data.
What is the key difference between BPC-157 and LL-37?
LL-37 is an endogenous antimicrobial peptide with immunomodulatory roles; BPC-157 is a synthetic gastric peptide - they address wound healing from completely different biological angles.
Evidence Comparison
BPC-157: 70+ rodent studies, single research group, no human efficacy data. LL-37: Strong human observational data in wound healing, approved clinical investigations (NCT numbers exist), but pathologically elevated in psoriasis/rosacea - making it a two-edged compound.
Evidence Context Favoring BPC-157
Musculoskeletal and GI injury research where the goal is systemic tissue repair signaling.
Evidence Context Favoring LL-37
Antimicrobial applications or research into innate immunity; LL-37 has the more credible antimicrobial evidence base.
Side-by-Side Snapshot
| Evidence grade | BPC-157: Level B LL-37: Level C |
|---|---|
| Research status | BPC-157: Phase 2 LL-37: Phase 1 |
| Primary category | BPC-157: Healing & Recovery LL-37: Immune Support |
| Cited studies | BPC-157: 10 LL-37: 2 |